<DOC>
	<DOCNO>NCT02360852</DOCNO>
	<brief_summary>This study evaluate safety , tolerability influence itching , bile acid liver enzyme change patient PBC ( Primary Biliary Cirrhosis ) treat A4250</brief_summary>
	<brief_title>IBAT Inhibitor A4250 Cholestatic Pruritus</brief_title>
	<detailed_description>A4250PBCpruritus ( EudraCT 2014-004070-42 ) open-label exploratory study . The primary objective study assess safety tolerability A4250 , 1.5 - 3 mg orally four-week treatment period , patient PBC cholestatic pruritus , determine occurrence treatment-emergent serious adverse event ( SAEs ) . Other safety objective study include assessment safety tolerability A4250 four-week treatment period , determine occurrence treatment-emergent adverse event ( AEs ) change safety parameter include liver kidney function test vital sign . Exploratory efficacy objective study demonstrate efficacy A4250 orally pruritus variable QoL lysophosphatidic acid formation well evaluation change pharmacodynamic parameter bile acid metabolism serum fecal bile acid , C4 fibroblast growth factor 19 ( FGF19 ) assessments assessment surrogate marker cholestatic liver disease alkaline phosphatase , transaminases bilirubin .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<criteria>Major Diagnosis PBC PBCAutoimmune hepatitis overlap establish accord American Association Study Liver Diseases/European Association Study Liver ( AASLD/EASL ) definition . Definite probable PBC diagnosis , demonstrate presence ≥ 2 follow 3 diagnostic factor : History elevate alkaline phosphatase ( ALP ) level ( &gt; 1.67 ULN ) least 6 month prior Day 1 Positive antimitochondrial antibody ( AMA ) titer AMA negative low titer ( &lt; 1:80 ) PBC specific antibody ( antiGP210 and/or antiSP100 and/or antibody major M2 component ( PDCE2 , 2oxoglutaric acid dehydrogenase complex ) Liver biopsy consistent PBC ; Ursodeoxycholic acid ( UDCA ) nonresponders define &gt; 6 month UDCA time enrolment serum ALP &gt; 1.67 ULN ; Laboratory marker cholestasis identify within 3 month Visit 1 ; Treatment cholestyramine dose &gt; 4g BID colestipol &gt; 5mg least 3 month ; The patient VASItch least 30 mm day baseline ( Visit 2 ) ; The patient male nonpregnant female ≥18 year age ≤80 year age body mass index ( BMI ) ≥18.5 &lt; 35 kg/m2 ; Major Any condition , opinion Investigator constitute risk patient contraindication participation completion study , could interfere study objective , conduct , evaluation ; Jaundice extrahepatic origin ; The patient structural abnormality GI tract ; The patient know , active , clinically significant acute chronic infection , major episode infection require hospitalization treatment parenteral anti infectives within 4 week treatment start ( study day 1 ) completion oral antiinfective treatment within 2 week prior start screen period ; The patient unexplained clinically significant GI alarm signal ( e.g. , low GI bleed hemepositive stool , irondeficiency anaemia , unexplained weight loss ) systemic sign infection colitis ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>